<DOC>
	<DOC>NCT01699659</DOC>
	<brief_summary>Hypothesis: The UAS Immunotherapy protocol is efficacious and at least as efficacious as protocols described in the Allergy literature.</brief_summary>
	<brief_title>The Efficacy &amp; Safety of the UAS Immunotherapy Protocol</brief_title>
	<detailed_description>Patients will be assessed for efficacy of the immunotherapy protocol by completing Consented-IRB approved clinical, medication, quality of life survey questions comparing current status while on therapy in contrast to 12 months before the inception of therapy.</detailed_description>
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
	<criteria>Allergic rhinitis between 18 and 65 years old who have chosen to undergo immunotherapy. No beta blocker use, no pregnancy, no systemic steroids, no severe asthma/copd, no severe collagen vascular disorders, no neoplastic or uncontrolled seizure activity, no previous anaphylaxis, no significant cardiovsacular disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Allergic Rhinitis</keyword>
	<keyword>Allergen Immunotherapy</keyword>
</DOC>